IP Library Granted Patent US 11,389,371
Granted Patent B2
US 11,389,371 · App. 15/984,505 · Granted Jul 19, 2022

Acoustic shock wave therapeutic methods

Inventor: John F. Warlick (Woodstock, GA)
Assignee: Softwave Tissue Regeneration Technologies, LLC
A61H23/008A61B8/085A61B8/13G10K15/043A61B2090/378A61H2201/0153A61H2201/1654A61H2201/50A61H2205/087
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,371
App. No.
15/984,505
Granted
Jul 19, 2022
Kind
B2
Abstract

A method of modulating glandular secretions by administering acoustic shock waves to a gland, includes the steps of activating acoustic shock waves of an acoustic shock wave generator to emit acoustic shock waves and subjecting the gland to acoustic shock waves stimulating the gland to have a modulated response. The modulated response is one of an adjustment in hormonal release which increases low level output, decreases high level output or stabilizes erratic output. The emitted acoustic shock waves are focused or unfocused low energy acoustic shock waves. The gland underlies the patient's skin. The shock wave generator is acoustically coupled to the patient's skin using a coupling gel or liquid. The gland is one of a testicle, ovary, pituitary gland, adrenal gland, thyroid gland, thymus, pineal gland, parathyroid, or hypothalamus. The method can be repeated one or more times.

Claims (20)

1. A method of modulating glandular secretions by administering acoustic shock waves to a gland of a patient, the gland is one of an ovary, a pituitary gland, an adrenal gland, a thyroid gland, a thymus, a pineal gland, a parathyroid, and a hypothalamus, the method comprises the steps of:

activating an acoustic shock wave generator to emit acoustic shock waves;

subjecting the gland to the acoustic shock waves to stimulate the gland to have a modulated response, wherein the modulated response is one of an adjustment in glandular secretions of hormonal release from the gland which increases low level hormonal output in the gland where the secretions are low relative to a normal level, or which decreases high level hormonal output in the gland where the secretions are high relative to a normal level, to stabilize erratic hormonal output in the gland to achieve the normal level of the glandular secretions; and

wherein the emitted acoustic shock waves are low energy soft waves, the soft waves being focused or unfocused acoustic shock waves having an energy density of less than 0.4 mJ/mm 2 , wherein the shock waves comprise amplitude above 0.1 MPa and rise times of the amplitude are below 100 nano-seconds with a duration of the acoustic shock waves being below 3 micro-seconds for a positive part of a cycle.

2. The method of claim 1 , wherein the shock wave generator is acoustically coupled to the patient's skin using a coupling gel or liquid.

3. The method of claim 1 , further comprising the step of stimulating the gland with a sufficient amount of acoustic shock waves to cause a release of nitric oxide.

4. The method of claim 3 , further comprising the step of stimulating the gland with a sufficient amount of acoustic shock waves to cause a release of growth factors including Vascular Endothelial Growth Factor (VEGF).

5. The method of claim 4 , further comprising the step of stimulating the gland with a sufficient amount of acoustic shock waves to cause new blood vessels to be created increasing vascularization.

6. The method of claim 1 , is repeated one or more times.

7. The method of claim 1 , wherein the low energy soft waves have the energy density in the range of 0.01 mJ/mm 2 to 0.4 mJ/mm 2 .

8. The method of claim 7 , wherein the low energy soft waves have the energy density in the range of 0.04 mJ/mm 2 to 0.3 mJ/mm 2 .

9. The method of claim 1 , wherein the gland receives between 100 and 2000 acoustic shock waves per therapy session.

10. The method of claim 1 , wherein the gland is an ovary.

11. The method of claim 10 , wherein the modulated response is an increase in a hormonal release of estrogen wherein a patient was exhibiting low levels of estrogen relative to a normal level of estrogen.

12. The method of claim 10 , wherein the modulated response is a decrease in a hormonal release of estrogen wherein a patient was exhibiting high levels of estrogen relative to a normal level of estrogen.

13. The method of claim 1 , wherein the modulated response reduces panic attacks and anxiety by decreasing levels of adrenaline by the adrenal gland.

14. A method of modulating glandular secretions by administering acoustic shock waves to a testicle of a patient to decrease a level of testosterone within the patient, comprises the steps of:

activating an acoustic shock wave generator to emit acoustic shock waves;

subjecting the gland to acoustic shock waves to stimulate the testicle to have a modulated response wherein the modulated response is an adjustment in glandular secretions of testosterone from the testicle which decreases high level testosterone output in the testicle to stabilize erratic hormonal output in the testicle where the secretions are high relative to a normal level to achieve the normal level of testosterone secretions; and

wherein the emitted acoustic shock waves are low energy soft waves, the soft waves being focused or unfocused acoustic shock waves having an energy density of less than 0.4 mJ/mm 2 , wherein the shock waves comprise amplitude above 0.1 MPa and rise times of the amplitude are below 100 nano-seconds with a duration of the acoustic shock waves being below 3 micro-seconds for a positive part of a cycle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2020
From: TISSUE REGENERATION TECHNOLOGIES, LLC
To: SOFTWAVE TISSUE REGENERATION TECHNOLOGIES, LLC
Reel/Frame 053946/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2020
From: WARLICK, JOHN F.
To: TISSUE REGENERATION TECHNOLOGIES, LLC
Reel/Frame 052322/0059 →
Continuity (1)
Related Publication 20190350803A1 · Nov 21, 2019